1. Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
   Nikolai Havn Sæther et al, 2018, Hered Cancer Clin Pract CrossRef
2. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer
   Siddhartha Yadav et al, 2017, Clinical Breast Cancer CrossRef
3. Effect of BRCA germline mutations on breast cancer prognosis
   Zora Baretta et al, 2016, Medicine CrossRef
4. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
   Jai Min Ryu et al, 2019, Breast Cancer Res Treat CrossRef
5. Mutations in tumor suppressor genes and their relationship with phenotypic features of breast cancer in young age women
   Lyudmila A. Gordeeva et al, 2018, Ecol genet CrossRef
6. Le cancer du sein triple-négatif. Le triple-négatif est fréquent chez les patientes mutées : comment ne pas le rater ? Comment le caractériser ? De manière plus générale, l’imagerie peut-elle orienter vers le diagnostic histologique ?
   Martine Boisserie-Lacroix et al, 2014, Imagerie de la Femme CrossRef
7. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer
   C. Wang et al, 2015 CrossRef
8. High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients
   Dagnija Kalniete et al, 2015, Hered Cancer Clin Pract CrossRef
9. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival
   Aye A. Thike et al, 2016, Histopathology CrossRef
10. Integrating mutation and gene expression cross-sectional data to infer cancer progression
    Julia L. Fleck et al, 2016, BMC Syst Biol CrossRef
11. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer
    Gilda Schmidt et al, 2016, J Cancer Res Clin Oncol CrossRef
12. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients
    Xiaorong Zhong et al, 2016, PLoS ONE CrossRef
13. Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features
    Touria Derkaoui et al, 2016, BMC Women's Health CrossRef
14. Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
    Katarzyna Pogoda et al, 2020, Journal of Oncology CrossRef
15. Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer
    Wookyeom Yang et al, 2016, Oncotarget CrossRef
16. Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients
    Sherihan AbdelHamid et al, 2021, Biology CrossRef
17. Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach
    Piotr Kedzierawski et al, 2021, Diagnostics CrossRef
18. Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine
    Anastasiia Samusieva et al, 2022, Breast Cancer Res Treat CrossRef
19. Evaluation of the results of neoadjuvant treatment in patients with HER2 positive breast cancer subtype
    Oleg I. Kaganov et al, 2022, Kazan Med J CrossRef
20. Implications of BRCA1 and BRCA2 Mutations in Mexico
    Carlos Arturo Gonzalez Nuñez et al, 2023 CrossRef
21. Risk of metastasis in BRCA2 carriers diagnosed with triple‐negative breast cancer
    Marcelo Moreno et al, 2023, Cancer Medicine CrossRef
22. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status
    Yuwei Wang et al, 2024, BMC Med CrossRef